Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations - Associated Press
Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations Associated Press
NEW YORK--(BUSINESS WIRE)--Feb 1, 2019--Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Comments
Post a Comment